Personalized Treatment Strategies
in the Management of Psoriasis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Lilly USA LLC and Novartis Pharmaceuticals

Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million, or just over 2%, of the population in the United States. The main disease activity leading to psoriasis occurs within the top 5 layers of the epidermis and most commonly appears on the skin of the scalp, elbow, knees, and lumbosacral areas of the body. Psoriasis is a periodic flare-up of itchy, sharply defined red patches covered by a silvery, flaky surface. The disease is complex to manage and a patient-centered treatment approach is encouraged as the goal is to reduce disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbidities. Unfortunately, the disease is under diagnosed and expensive to treat thus early diagnosis and treatment are likely to reduce the economic burden. Choosing the most effective therapy depends on factors such as the location, severity and type of psoriasis. Topical agents remain the standard treatment in the first line setting, however patient adherence is quite poor. Systemic medication is prescribed orally or by injection while photo or laser therapy are also effective yet expensive and require frequent doctor visits; adding to the disease burden. Fortunately, novel oral medications which target small molecules and biologics have shown efficacy in clinical trials. Recent research indicates that both IL-23 and IL-17 pathways play important, and perhaps integral roles in the development of psoriatic plaques.

Upon Completion of this activity, participants will be able to:

  • Analyze individualized treatment plans for patients with psoriasis using clinical safety and efficacy data

  • Examine the most up-to-date diagnostic criteria and standard treatment options for early and moderate to severe patients with psoriasis

  • Evaluate practical treatment considerations for patients with psoriasis who have challenging comorbidities

  • Identify recent biological therapies with interleukin-17 (IL-17) and IL-23 pathway inhibitors in patients with moderate to severe psoriasis

  • Assess the improved psoriasis pathogenesis and how recent developments help increase effective systemic agents to treat patients

Faculty: Junko Takeshita, MD, PhD, MSCE
Assistant Professor of Dermatology
Assistant Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine


Dr.Takeshita's presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Lilly USA LLC and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue